<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Intern Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Intern. Med</journal-id>
      <journal-id journal-id-type="doi">10.2169/internalmedicine.55.7185</journal-id>
      <journal-title-group>
        <journal-title>Internal Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0918-2918</issn>
      <issn pub-type="epub">1349-7235</issn>
      <publisher>
        <publisher-name>The Japanese Society of Internal Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27904122</article-id>
      <article-id pub-id-type="pmc">5216156</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Triptan-induced Reversible Cerebral Vasoconstriction Syndrome: Two Case Reports with a Literature Review</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kato</surname>
            <given-names>Yuji</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hayashi</surname>
            <given-names>Takeshi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mizuno</surname>
            <given-names>Satoko</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Horiuchi</surname>
            <given-names>Yohsuke</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ohira</surname>
            <given-names>Masayuki</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tanahashi</surname>
            <given-names>Norio</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takao</surname>
            <given-names>Masaki</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Department of Neurology and Cerebrovascular Medicine, Saitama Medical University International Medical Center, Japan</aff>
      </contrib-group>
      <author-notes>
        <fn>
          <p>Correspondence to Dr.&#x3000;Yuji Kato, <email>yujik@saitama-med.ac.jp</email></p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>1</day>
        <month>12</month>
        <year>2016</year>
      </pub-date>
      <volume>55</volume>
      <issue>23</issue>
      <fpage>3525</fpage>
      <lpage>3528</lpage>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>1</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>4</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p><!--CREATIVE COMMONS-->The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>We encountered two patients with sumatriptan-induced reversible cerebral vasoconstriction syndrome (RCVS). The present patients were taking sumatriptan for the first time because they had been tentatively diagnosed with a migraine. On reviewing the literature, we found nine other cases of triptan-induced RCVS, predominantly among women aged 30 to 40 years. RCVS has been precipitated by triptan at the first ever use, after daily use, and even with long-term use at a normal dose. Patients with acute onset of severe headache should be thoroughly evaluated, and triptan should be administered appropriately. If triptan-induced RCVS is suspected, vascular imaging should be repeated after several days. </p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>reversible cerebral vasoconstriction syndrome</kwd>
        <kwd>triptan</kwd>
        <kwd>migraine</kwd>
        <kwd>thunderclap headache</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>Reversible cerebral vasoconstriction syndrome (RCVS) is a clinical entity characterized by severe headaches with or without acute neurological symptoms, the radiological features of which include multifocal segmental constriction of the cerebral arteries that resolves spontaneously within three months (<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B4" ref-type="bibr">4</xref>). RCVS is considered a rare syndrome, but the growing use of vasoactive drugs combined with the more frequent use of non-invasive neurovascular imaging has increased the incidence (<xref rid="B4" ref-type="bibr">4</xref>). Triptan is one of the drugs that triggers RCVS (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B4" ref-type="bibr">4</xref>), but triptan-induced RCVS cases are relatively rare. We herein describe two cases of sumatriptan-induced RCVS and review the clinical features of triptan-induced RCVS.</p>
    </sec>
    <sec>
      <title>Case Reports</title>
      <sec>
        <title>Case 1</title>
        <p>A 43-year-old woman with a history of uncontrolled hypertension began suffering from a bifrontal-throbbing headache every other day, associated with neither nausea, photophobia, nor phonophobia. Three weeks later, she sought medical attention when over-the-counter medications failed to relive the headaches. The results of a computed tomographic (CT) scan of the head were normal, and she was prescribed oral sumatriptan. One hour after taking the drug, she experienced a sudden exacerbation of her headache, followed by a seizure, which caused her to fall and hit her head against the floor. She was subsequently admitted to our institute.</p>
        <p>On admission, her blood pressure was 171/72 mmHg, and she was afebrile. Shortly thereafter, she again experienced a generalized epileptic seizure that was treated by intravenous administration of diazepam and phenytoin. The laboratory findings, including a blood count, coagulation parameters, and the results of liver and renal tests, were normal. Magnetic resonance imaging (MRI) of the brain using fluid-attenuated inversion recovery (FLAIR) revealed a left parietal cortical subarachnoid hemorrhage (SAH) (<xref ref-type="fig" rid="g001">Fig. 1a</xref>, small white arrow) and multiple high-intensity lesions in the bilateral occipital lobes (<xref ref-type="fig" rid="g001">Fig. 1a</xref>, large black arrows). Diffusion-weighted MRI and magnetic resonance angiography (MRA) revealed no abnormalities (<xref ref-type="fig" rid="g001">Fig. 1b</xref>). On Day 6, MRA showed narrowing of the bilateral middle and posterior cerebral arteries (<xref ref-type="fig" rid="g001">Fig. 1d</xref>, white arrows), although the lesions on the occipital lobes had improved (<xref ref-type="fig" rid="g001">Fig. 1c</xref>). Her blood pressure was controlled within a normal range through administration of first amlodipine and then lomerizine. On Day 14, her headache had improved, and findings on MRI and MRA were normal (<xref ref-type="fig" rid="g001">Fig. 1e and f</xref>). She was diagnosed with a headache attributed to arterial hypertension before sumatriptan administration, and RCVS associated with posterior reversible encephalopathy syndrome (PRES). The cortical SAH might have been due either to the head trauma or to RCVS.</p>
        <fig id="g001" orientation="portrait" position="float">
          <label>Figure 1.</label>
          <caption>
            <p>a: FLAIR-MRI on admission showing a left parietal cortical subarachnoid hemorrhage (small white arrow), multiple lesions on the bilateral occipital lobes (large black arrows), and traumatic scalp hematoma (black arrowhead). b: MRA on admission showing no abnormalities. c: FLAIR-MRI on Day 6 showing the resolution of the occipital lesions. d: MRA on Day 6 showing a beaded appearance of the bilateral middle and posterior cerebral arteries (white arrows). e: FLAIR-MRI on Day 14 showing no additional findings. f: MRA on Day 14 showing the resolution of the narrowing vessels.</p>
          </caption>
          <graphic xlink:href="1349-7235-55-3525-g001"/>
        </fig>
      </sec>
      <sec>
        <title>Case 2</title>
        <p>A 30-year-old woman developed a bifrontal-throbbing headache 4 days after spontaneous delivery. The pregnancy had been uneventful, and she never had signs of eclampsia. She had no remarkable medical history. On admission, had blood pressure was 180/104 mmHg. The findings from a neurological examination and initial CT scan were normal. The brain MRI with MRA findings were also normal (<xref ref-type="fig" rid="g002">Fig. 2a and b</xref>). She was treated with nasal sumatriptan, but the headaches initially showed no response. The headaches then gradually resolved following the administration of acetaminophen over a few days, and the patient was discharged. A repeat MRI with MRA performed on Day 6 after her discharge showed narrowing of the bilateral anterior, middle, and posterior cerebral arteries (<xref ref-type="fig" rid="g002">Fig. 2c and d</xref>, white arrows), which were normalized on Day 25 (<xref ref-type="fig" rid="g002">Fig. 2e and f</xref>). In this case, the headache peaked during the first few days following sumatriptan administration and disappeared before the peak of cerebral vasoconstriction. She was retrospectively suspected of having had a postpartum headache before starting sumatriptan administration.</p>
        <fig id="g002" orientation="portrait" position="float">
          <label>Figure 2.</label>
          <caption>
            <p>a, b: MRA on admission showing no abnormalities. c, d: MRA on Day 7 showing a diffuse, beaded appearance of the intracranial vasculature (white arrows). e, f: MRA on Day 25 showing the complete resolution of the narrowing vessels.</p>
          </caption>
          <graphic xlink:href="1349-7235-55-3525-g002"/>
        </fig>
      </sec>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>Sumatriptan is often used to treat migraines and occasionally induces cerebral vasoconstriction. Our two patients were taking sumatriptan for the first time because they had been tentatively diagnosed with a migraine. It was difficult to show any clear evidence of sumatriptan-induced RCVS in both of these cases. Sumatriptan seemed to play a primary role in Case 1, but a secondary role or even an incidental role due to the postpartum period in Case 2. However, sumatriptan likely either induced or exacerbated RCVS in both cases. </p>
      <p>The recent literature reflects a growing interest in RCVS. Four studies including more than 10 cases have been published (<xref rid="B5" ref-type="bibr">5</xref>-<xref rid="B8" ref-type="bibr">8</xref>). However, only nine cases in the literature have described the association between triptans and RCVS in detail (<xref ref-type="table" rid="t001">Table</xref>) (<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B9" ref-type="bibr">9</xref>-<xref rid="B14" ref-type="bibr">14</xref>). The mean age among these 9 cases was 36 years, and 6 (66.7%) were women. Sumariptan, administrated either subcutaneously, orally, or nasally, was the most commonly implicated drug. RCVS was precipitated at the first ever use, or after daily use of one or several drugs, or even after long-term use of triptan at normal doses. Two patients presented with RCVS within the first week after delivery, suggesting that triptans must be used carefully in patients with headache in the postpartum period. The most frequent finding on cerebral imaging was ischemic stroke (four cases). Only two patients presented with thunderclap headache. Most patients had good recovery, but severe stroke seemed to induce poor outcomes.</p>
      <table-wrap id="t001" orientation="portrait" position="float">
        <label>Table.</label>
        <caption>
          <p>Case Reports of RCVS and Triptan Use.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead style="border-top:solid thin; border-bottom:solid thin;">
            <tr>
              <th align="center" valign="middle" rowspan="1" colspan="1">Reference</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Age/sex</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Trigger drug</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Postpartum <break/>period</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Subarachnoid <break/>hemorrhage</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Stroke</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Headache characteristics</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Clinical outcome</th>
            </tr>
          </thead>
          <tbody style="border-top:solid thin; border-bottom:solid thin;">
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">9</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">43M</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Sumatriptan&#x2020; (T), Midrin&#x2020;</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Ischemic</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Bioccipital-throbbing</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Recovery</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">10</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">20F</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Sumatriptan* (I), Ergotamine*</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Ischemic</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Severe frontal and occipitonuchal</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Recovery</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">11</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">37F</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Sumatriptan&#x2020; (I), Ergotamine&#x2020;</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Hemorrhage</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Frontal throbbing</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Impairment</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">12</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">34M</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Sumatriptan (I) &#x2020;</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Ischemic</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Nonconscious</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Recovery</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">13</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">12M</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Eletriptan (T)</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Severe acute</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Recovery</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">14</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">39F</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Naratriptan (T) &#x2020;, SNRI, SSRI</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Severe bifrontal-throbbing</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Recovery</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">7</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">68F</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Sumatriptan (?)</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Ischemic</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Thunderclap</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Death</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">Present case 1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">44F</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Sumatriptan* (T)</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">PRES</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Thunderclap</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Recovery</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">Present case 2</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">30F</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Sumatriptan* (N)</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">No</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Bifrontal-throbbing</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Recovery</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>(T) Tablet, (N) Nasal spray, (I) Injection, * First ever use, &#x2020; Abuse or daily use, SNRI: serotonin norepinephrine reuptake inhibitor, SSRI: selective serotonin reuptake inhibitor, PRES: posterior reversible encephalopathy syndrome</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>The underlying mechanisms of RCVS are unknown. Triptan can precipitate RCVS when administered to susceptible patients. An individual's susceptibility to developing RCVS may be influenced by genetic predisposition (e.g., brain-derived neurotrophic polymorphism, female gender) and precipitating factors (e.g., vasoactive substances, pregnancy/postpartum) (<xref rid="B15" ref-type="bibr">15</xref>). Triptan-induced RCVS may be more frequent than previously thought. Regardless of the presence of a migraine, patients presenting with acute onset of severe headache should be thoroughly evaluated, and triptan should be administered carefully, as it could precipitate RCVS or aggravate cerebral vasoconstriction. If triptan-induced RCVS is suspected, vascular imaging should be performed after several days.</p>
    </sec>
    <sec>
      <title>The authors state that they have no Conflict of Interest (COI).</title>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calabrese</surname><given-names>LH</given-names></name>, <name><surname>Dodick</surname><given-names>DW</given-names></name>, <name><surname>Schwedt</surname><given-names>TJ</given-names></name>, <name><surname>Singhal</surname><given-names>AB</given-names></name></person-group>
<article-title>Narrative review: reversible cerebral vasoconstriction syndromes</article-title>. <source>Ann Intern Med</source>
<volume>146</volume>: <fpage>34</fpage>-<lpage>44</lpage>, <year>2007</year>.<pub-id pub-id-type="pmid">17200220</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ducros</surname><given-names>A</given-names></name></person-group>
<article-title>Reversible cerebral vasoconstriction syndrome</article-title>. <source>Lancet Neurol</source>
<volume>11</volume>: <fpage>906</fpage>-<lpage>917</lpage>, <year>2012</year>.<pub-id pub-id-type="pmid">22995694</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><collab>Headache Classification Committee of the International Headache Society (IHS)</collab>. </person-group><article-title>The International Classification of Headache Disorders, 3rd edition (beta version)</article-title>. <source>Cephalalgia</source>
<volume>33</volume>: <fpage>629</fpage>-<lpage>808</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23771276</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yancy</surname><given-names>H</given-names></name>, <name><surname>Lee-Iannotti</surname><given-names>JK</given-names></name>, <name><surname>Schwedt</surname><given-names>TJ</given-names></name>, <name><surname>Dodick</surname><given-names>DW</given-names></name></person-group>
<article-title>Reversible cerebral vasoconstriction syndrome</article-title>. <source>Headache</source>
<volume>53</volume>: <fpage>570</fpage>-<lpage>576</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23489219</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ducros</surname><given-names>A</given-names></name>, <name><surname>Boukobza</surname><given-names>M</given-names></name>, <name><surname>Porcher</surname><given-names>R</given-names></name>, <name><surname>Sarov</surname><given-names>M</given-names></name>, <name><surname>Valade</surname><given-names>D</given-names></name>, <name><surname>Bousser</surname><given-names>MG</given-names></name></person-group>
<article-title>The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients</article-title>. <source>Brain</source>
<volume>130</volume>: <fpage>3091</fpage>-<lpage>3101</lpage>, <year>2007</year>.<pub-id pub-id-type="pmid">18025032</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singhal</surname><given-names>AB</given-names></name>, <name><surname>Hajj-Ali</surname><given-names>RA</given-names></name>, <name><surname>Topcuoglu</surname><given-names>MA</given-names></name>, <etal>et al</etal></person-group>
<article-title>Reversible cerebral vasoconstriction syndromes: analysis of 139 cases</article-title>. <source>Arch Neurol</source>
<volume>68</volume>: <fpage>1005</fpage>-<lpage>1012</lpage>, <year>2011</year>.<pub-id pub-id-type="pmid">21482916</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Robert</surname><given-names>T</given-names></name>, <name><surname>Kawkabani Marchini</surname><given-names>A</given-names></name>, <name><surname>Oumarou</surname><given-names>G</given-names></name>, <name><surname>Usk&#xE9;</surname><given-names>A</given-names></name></person-group>
<article-title>Reversible cerebral vasoconstriction syndrome identification of prognostic factors</article-title>. <source>Clin Neurol Neurosurg</source>
<volume>115</volume>: <fpage>2351</fpage>-<lpage>2357</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">24021453</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katz</surname><given-names>BS</given-names></name>, <name><surname>Fugate</surname><given-names>JE</given-names></name>, <name><surname>Ameriso</surname><given-names>SF</given-names></name>, <etal>et al</etal></person-group>
<article-title>Clinical worsening in reversible cerebral vasoconstriction syndrome</article-title>. <source>JAMA Neurol</source>
<volume>71</volume>: <fpage>68</fpage>-<lpage>73</lpage>, <year>2014</year>.<pub-id pub-id-type="pmid">24190097</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meschia</surname><given-names>JF</given-names></name>, <name><surname>Malkoff</surname><given-names>MD</given-names></name>, <name><surname>Biller</surname><given-names>J</given-names></name></person-group>
<article-title>Reversible segmental cerebral arterial vasospasm and cerebral infarction: possible association with excessive use of sumatriptan and Midrin</article-title>. <source>Arch Neurol</source>
<volume>55</volume>: <fpage>712</fpage>-<lpage>714</lpage>, <year>1998</year>.<pub-id pub-id-type="pmid">9605729</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Granier</surname><given-names>I</given-names></name>, <name><surname>Garcia</surname><given-names>E</given-names></name>, <name><surname>Geissler</surname><given-names>A</given-names></name>, <name><surname>Boespflug</surname><given-names>MD</given-names></name>, <name><surname>Durand-Gasselin</surname><given-names>J</given-names></name></person-group>
<article-title>Postpartum cerebral angiopathy associated with the administration of sumatriptan and dihydroergotamine: a case report</article-title>. <source>Intensive Care Med</source>
<volume>25</volume>: <fpage>532</fpage>-<lpage>534</lpage>, <year>1999</year>.<pub-id pub-id-type="pmid">10401952</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nighoghossian</surname><given-names>N</given-names></name>, <name><surname>Derex</surname><given-names>L</given-names></name>, <name><surname>Trouillas</surname><given-names>P</given-names></name></person-group>
<article-title>Multiple intracerebral hemorrhages and vasospasm following antimigrainous drug abuse</article-title>. <source>Headache</source>
<volume>38</volume>: <fpage>478</fpage>-<lpage>480</lpage>, <year>1998</year>.<pub-id pub-id-type="pmid">9664756</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singhal</surname><given-names>AB</given-names></name>, <name><surname>Caviness</surname><given-names>VS</given-names></name>, <name><surname>Begleiter</surname><given-names>AF</given-names></name>, <name><surname>Mark</surname><given-names>EJ</given-names></name>, <name><surname>Rordorf</surname><given-names>G</given-names></name>, <name><surname>Koroshetz</surname><given-names>WJ</given-names></name></person-group>
<article-title>Cerebral vasoconstriction and stroke after use of serotonergic drugs</article-title>. <source>Neurology</source>
<volume>58</volume>: <fpage>130</fpage>-<lpage>133</lpage>, <year>2002</year>.<pub-id pub-id-type="pmid">11781419</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>S</given-names></name>, <name><surname>Takano</surname><given-names>T</given-names></name>, <name><surname>Ryujin</surname><given-names>F</given-names></name>, <name><surname>Takeuchi</surname><given-names>Y</given-names></name></person-group>
<article-title>A pediatric case of reversible cerebral vasoconstriction syndrome with cortical subarachnoid hemorrhage</article-title>. <source>Brain Dev</source>
<volume>34</volume>: <fpage>796</fpage>-<lpage>798</lpage>, <year>2012</year>.<pub-id pub-id-type="pmid">22285527</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ba</surname><given-names>F</given-names></name>, <name><surname>Giuliani</surname><given-names>F</given-names></name>, <name><surname>Camicioli</surname><given-names>R</given-names></name>, <name><surname>Saqqur</surname><given-names>M</given-names></name></person-group>
<article-title>A reversible cerebral vasoconstriction syndrome</article-title>. <source>BMJ Case Rep</source>
<volume>2012</volume>: <fpage>bcr0920114841</fpage>, <year>2012</year>.</mixed-citation>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>SP</given-names></name>, <name><surname>Fuh</surname><given-names>JL</given-names></name>, <name><surname>Wang</surname><given-names>SJ</given-names></name>, <name><surname>Tsai</surname><given-names>SJ</given-names></name>, <name><surname>Hong</surname><given-names>CJ</given-names></name>, <name><surname>Yang</surname><given-names>AC</given-names></name></person-group>
<article-title>Brain-derived neurotrophic factor gene Val66Met polymorphism modulates reversible cerebral vasoconstriction syndromes</article-title>. <source>PLoS One</source>
<volume>6</volume>: <fpage>e18024</fpage>, <year>2011</year>.<pub-id pub-id-type="pmid">21437208</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
